China NT Pharma Group Co., Ltd. (HK:1011)
:1011
Want to see HK:1011 full AI Analyst Report?
1011 Stock Chart & Stats
HK$0.84
<HK$0.01(0.40%)
At close: 4:00 PM EST
HK$0.84
<HK$0.01(0.40%)
Day’s Range― - ―
52-Week RangeHK$0.40 - HK$1.35
Previous CloseN/A
Volume22.00K
Average Volume (3M)1.68M
Market Cap
HK$578.89M
Enterprise ValueHK$657.45M
Total Cash (Recent Filing)HK$7.22M
Total Debt (Recent Filing)HK$316.83M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding948,997,700
10 Day Avg. Volume1,250,790
30 Day Avg. Volume1,683,352
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-1.66
Price to Sales (P/S)18.81
P/FCF Ratio-18.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CNS Specialty FocusA narrow therapeutic focus on CNS specialty drugs provides durable strategic clarity and higher entry barriers versus commodity generics. Specialized R&D and commercial know-how can support differentiated products, pricing power in niche markets, and more predictable regulatory pathways over months.
Recent Revenue ReboundA 2025 revenue recovery (+~26% YoY) suggests demand or commercial execution is returning after earlier declines. Sustained top-line recovery over several quarters supports scale benefits, stabilizes customer relationships, and creates a platform to leverage fixed-cost base for margin recovery.
Gross Margin ImprovementA large gross-margin improvement indicates better product mix, pricing, or manufacturing efficiency that can persist if the company sustains higher-value products. Higher gross margins materially increase the potential for operating leverage as revenues recover, helping long-term profitability prospects.
Bears Say
Negative Shareholders' EquityNegative equity reflects cumulative losses and materially weakens the capital structure. This elevates insolvency and refinancing risk, reduces strategic flexibility for R&D or M&A, and can limit access to conventional financing, pressuring durability of operations over months.
Persistent Heavy LossesVery large negative operating and net margins indicate core operations are not yet profitable. Ongoing structural losses erode capital, impede reinvestment in R&D or commercialization, and mean the company must address fundamentals before consistent, durable earnings can be achieved.
Return To Cash BurnReversion to negative operating and free cash flow increases dependency on external financing. In a negative-equity and high-debt context, recurring cash burn heightens the risk of dilution, covenant breaches, or costly refinancing, which threatens operational continuity over the medium term.
China NT Pharma Group Co., Ltd. News
1011 FAQ
What was China NT Pharma Group Co., Ltd.’s price range in the past 12 months?
China NT Pharma Group Co., Ltd. lowest stock price was HK$0.40 and its highest was HK$1.35 in the past 12 months.
What is China NT Pharma Group Co., Ltd.’s market cap?
China NT Pharma Group Co., Ltd.’s market cap is HK$578.89M.
When is China NT Pharma Group Co., Ltd.’s upcoming earnings report date?
China NT Pharma Group Co., Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were China NT Pharma Group Co., Ltd.’s earnings last quarter?
China NT Pharma Group Co., Ltd. released its earnings results on Mar 31, 2026. The company reported -HK$0.015 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.015.
Is China NT Pharma Group Co., Ltd. overvalued?
According to Wall Street analysts China NT Pharma Group Co., Ltd.’s price is currently Overvalued.
Does China NT Pharma Group Co., Ltd. pay dividends?
China NT Pharma Group Co., Ltd. pays a Annually dividend of HK$0.035 which represents an annual dividend yield of N/A. See more information on China NT Pharma Group Co., Ltd. dividends here
What is China NT Pharma Group Co., Ltd.’s EPS estimate?
China NT Pharma Group Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China NT Pharma Group Co., Ltd. have?
China NT Pharma Group Co., Ltd. has 948,997,700 shares outstanding.
What happened to China NT Pharma Group Co., Ltd.’s price movement after its last earnings report?
China NT Pharma Group Co., Ltd. reported an EPS of -HK$0.015 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.389%.
Which hedge fund is a major shareholder of China NT Pharma Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1011
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China NT Pharma Group Co., Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.15%
12-Months-Change
Fundamentals
Return on Equity
9.46%
Trailing 12-Months
Asset Growth
8.82%
Trailing 12-Months
Company Description
China NT Pharma Group Co., Ltd.
China NT Pharma Group Company Limited, together with its subsidiaries, engages in the research and development, manufacturing, sales, and distribution of pharmaceutical products in the People's Republic of China and internationally. It manufactures, sells, and trades in prescription medicines for the tumor and blood system diseases, digestive system diseases, central nervous system diseases, diseases of respiratory system, and other therapeutic fields; and produces and sells NT branded products and generic drugs. The company also provides marketing and promotion services to suppliers, and logistics and consulting services. China NT Pharma Group Company Limited was founded in 1995 and is headquartered in Suzhou, the People's Republic of China.
Technical Analysis
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
China Shineway Pharmaceutical Group Limited
―